Below are the financial statements of Immunovant, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in thousands of USD | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating expenses | — | — | — |
| Research and development | -360,917a | -212,928a | -160,257a |
| Acquired in-process research and development | 0a | -12,500a | -10,000a |
| General and administrative | -77,235a | -57,281a | -48,019a |
| Total operating expenses | -438,152a | -282,709a | -218,276a |
| Interest income | -24,732a | -24,948a | -7,578a |
| Other (income) expense, net | -471a | 1,008a | 253a |
| Loss before provision for income taxes | -412,949a | -258,769a | -210,951a |
| Provision for income taxes | -891a | -567a | -9a |
| Net loss | -413,840a | -259,336a | -210,960a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Immunovant’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.